Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis - Test2 - elhamkhani - TriplyDB

Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis

Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis

http://www.wikidata.org/entity/Q36051510

about

Risk of cancer in diabetes: the effect of metformin Potential increased risk of cancer from commonly used medications: an umbrella review of meta-analyses Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review The links between insulin resistance, diabetes, and cancer Lung cancer chemoprevention: current status and future prospects Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis Adherence to oral diabetes medications and glycemic control during and following breast cancer treatment.Hyperglycemia as a risk factor for cancer progression Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies Impact of glucose-lowering agents on the risk of cancer in type 2 diabetic patients. The Barcelona case-control study Effect of metformin on cancer risk and treatment outcome of prostate cancer: a meta-analysis of epidemiological observational studies Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts Incidence and Mortality Risks of Cancer in Patients with Type 2 Diabetes: A Retrospective Study in Shanghai, China Use of metformin alone is not associated with survival outcomes of colorectal cancer cell but AMPK activator AICAR sensitizes anticancer effect of 5-fluorouracil through AMPK activation Diabetes and cancer: Associations, mechanisms, and implications for medical practice.The effect of metformin on survival of patients with pancreatic cancer: a meta-analysis Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders.Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium.Diabetic oncopathy--one more yet another deadly diabetic complication!Metformin in cancer prevention and therapy.Effects of metformin on retinoblastoma growth in vitro and in vivo.Diabetes mellitus and risk of bladder cancer: a meta-analysis of cohort studies.Risk factors for pancreatic cancer: a summary review of meta-analytical studies.Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies.Impact of preoperative diabetes on long-term survival after curative resection of pancreatic adenocarcinoma: a systematic review and meta-analysis.Use of noninsulin anti diabetics for prevention and treatment of cancer- narrative review article.Diabetes and Insulin Therapy, but Not Metformin, Are Related to Hepatocellular Cancer Risk Type 2 Diabetes and Breast Cancer: The Interplay between Impaired Glucose Metabolism and Oxidant Stress Metformin inhibits growth of lung adenocarcinoma cells by inducing apoptosis via the mitochondria-mediated pathway.A Population-Based Cohort Study of All-Cause and Site-Specific Cancer Incidence Among Patients With Type 1 Diabetes Mellitus in Taiwan.Association between Insulin Monotherapy versus Insulin plus Metformin and the Risk of All-Cause Mortality and Other Serious Outcomes: A Retrospective Cohort Study Metformin and Not Diabetes Influences the Survival of Resected Early Stage NSCLC Patients.Risk factors for cancer development in type 2 diabetes: A retrospective case-control study Diabetes mellitus and the risk of bladder cancer: an Italian case–control study.Metformin use and risk of prostate cancer: results from the REDUCE study.Insulin therapy and cancer in type 2 diabetes.New-onset type 2 diabetes, elevated HbA1c, anti-diabetic medications, and risk of pancreatic cancer.Pharmacological Modulation of Lung Carcinogenesis in Smokers: Preclinical and Clinical Evidence.Diabetes and risk of cancer.

P2860

Q21284807-BD0D0D56-9372-4D55-BB70-363EAD71F477 Q24289205-F161F67C-513B-4C6F-BB88-BAF8BD733003 Q26850912-5D745B2D-C0A4-49BE-BBE7-6C3FDBB9F585 Q26852910-3F674251-06BE-485E-84CF-3A827F49A1F9 Q26995495-6F706970-B213-433F-B2BF-AE41083FCEE0 Q27002540-21976B9A-1250-419E-A252-1084CC48EA5E Q27331637-2228DF65-2631-4B9B-B439-2933B5258C12 Q27687614-E31DDA7D-BB20-4F2D-8363-4FA9E519BD16 Q28074225-D94FADD3-84F7-4331-9402-70D6A10D27B1 Q28084927-817BB4D1-3BDA-4E23-AC0A-D05EAE593FCA Q28535372-F3F41389-2E1E-4115-AE9E-9DD4E73128A3 Q28542914-D4E847BB-FD8C-4B3F-A224-2FF2D233AA0B Q28552408-586FFBE4-EF8B-4105-B92E-0A6E7F95D9C3 Q28597192-390B101C-CAF0-46E3-A580-E136BB6E5BA7 Q33645356-017F03A9-2C44-4C3A-8734-C747290C67A9 Q33759594-F5E8EFE7-ADEB-4FD7-B1B4-F9ADE03964D7 Q33919105-AEAFD55F-E6B9-46E9-B343-06AB436BDF78 Q34135248-9EAF5AF7-7368-4D5E-887A-4E2B49BBCFB9 Q34250010-40127901-BCAF-4772-8811-7FB250644A80 Q34272097-E598CDF8-3F0F-4F3A-807E-2BEC98C6B027 Q34357983-847F3A97-AA4D-4DA0-A7CB-65E8B5801686 Q34432841-21742B1C-BFF5-43C0-A238-46EC3259BAF6 Q34599224-AF655282-DDE6-4725-A868-F584D6EF57B5 Q34667061-F35CD451-AFF8-4830-9FF0-882A642655C1 Q35038355-18D17F17-6217-4A10-8E27-38C33A9CC30A Q35063344-C4E0C847-CC93-45EA-A350-1019F7D671BB Q35466765-298C1084-2E8B-4DBD-B325-2ABF2F04B21A Q35649664-BB88D90C-B311-4497-A836-382BDCE7F051 Q35782187-E30E2F9A-DE0A-4D7A-9D85-21BE50B1C3E8 Q35944480-6C16611E-FF5C-463A-B613-17D5732B56A4 Q35996287-7146BD37-80C7-4DF8-8493-3297A6E5A02F Q36010556-EFB272F0-7E63-45AB-97BE-3C957DC4BBBA Q36131775-2E9D17BC-0583-4D99-B647-9428C1A22070 Q36159846-6AF6BB5E-0C61-43EB-8357-1113289A22A4 Q36286678-3EE2FF56-59A6-4D38-B157-DEB2F5229971 Q36296255-E06C1BFC-953E-4BEE-9B0E-9E63370A235C Q36417868-B6BE1EA0-2835-4ECC-B46B-9EED21D84546 Q36443863-5BE96C64-F0E7-4C05-A8FE-F27835D0047E Q36505700-A9E489D6-1397-4356-83C7-404CD13B29AB Q36637909-CB0D941C-758E-4F99-B126-08A2B9927E46

P2860

Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis

http://www.wikidata.org/entity/Q36051510

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Cancer risk associated with us ...... pe 2 diabetes: a meta-analysis

@ast

Cancer risk associated with us ...... pe 2 diabetes: a meta-analysis

@en

type

label

Cancer risk associated with us ...... pe 2 diabetes: a meta-analysis

@ast

Cancer risk associated with us ...... pe 2 diabetes: a meta-analysis

@en

prefLabel

Cancer risk associated with us ...... pe 2 diabetes: a meta-analysis

@ast

Cancer risk associated with us ...... pe 2 diabetes: a meta-analysis

@en

P1433

Q36051510-4912107F-1F7C-4E9D-9D05-A2B5A096E5FA

P1476

Q36051510-6EB78533-308B-4AA3-9318-0F7A165BFD5E

P2093

Q36051510-85D7E785-4D59-4734-BFB7-5DC6E103EAE7

Q36051510-B284F351-55AE-49A5-9E16-293DB7C55181

Q36051510-EA44020D-2684-4F52-87A6-28D541AE6616

Q36051510-F8406274-CA17-4B85-846D-96AFFED3A6E1

P2860

Q36051510-01ACDC80-135D-4170-835E-12ACAA10CB8C

Q36051510-06AD1EBE-F31F-4FB5-A997-D1603439CD12

Q36051510-0704D50A-BFD6-4B91-98F9-01CECBAEDAD5

Q36051510-08B1EE0B-8801-4ABC-8871-0B3319D4792D

Q36051510-13293374-3BB5-4285-A1FA-20A7C8F4B715

Q36051510-2283F490-DB63-41DC-AB1E-CC2148EF188F

Q36051510-2650411C-24B0-4354-BE0F-3D42AF48932F

Q36051510-279C16D3-0F35-430D-ABDC-A7BDB7ADD2B4

Q36051510-295F5B9A-1A19-4031-A09A-2BED280DA33C

Q36051510-2AB73D73-91A0-433A-AFE2-96E0C6394F0A

P304

Q36051510-AFAD827D-A800-44F4-934A-D13799E2E46B

P31

Q36051510-5a69213e-7e4e-4c70-b1ab-3cb0ec8ced8e

Q36051510-D8E071C8-9841-4E89-B12E-4FCE75235BFB

P356

Q36051510-ADE5AE7C-EF52-4549-8588-0FBD7BAF22A2

P433

Q36051510-C796698A-348D-447C-BD7B-421F427587FE

P478

Q36051510-A3F4C37A-1164-40D1-A560-2751647882C1

P50

Q36051510-09AE85F9-075C-493F-B452-5C1C3B19535B

Q36051510-D3C482B0-D006-47D1-A12F-0F905402E07A

Q36051510-E51E4316-65A7-4A2E-9837-173F10354696

Q36051510-EFB9B971-A9CC-4F85-93BF-332A550B1002

Q36051510-F031CAFE-E21A-40ED-BF2B-6966D4CFE8DE

P577

Q36051510-A79AFAD6-0A86-43F8-A8BA-FAD38D30108F

P5875

Q36051510-8105B408-4AB9-42F9-AA80-A1FA46CA3459

P698

Q36051510-C62671BF-3B5A-418C-A0E3-9A9B42C67C5C

P921

Q36051510-336960B3-C45F-40BD-AE15-318082DE21EF

Q36051510-3BDA59B9-06D5-4ED2-8409-8FDCE91079B4

P932

Q36051510-3C01B09F-4C31-4AD7-85E3-8715580F4628

P356

THEONCOLOGIST.2011-0462

P1433

P1476

Cancer risk associated with us ...... pe 2 diabetes: a meta-analysis

@en

P2093

Cristina Bosetti

http://www.w3.org/2001/XMLSchema#string

Giovanni Corrao

http://www.w3.org/2001/XMLSchema#string

Guido Grassi

http://www.w3.org/2001/XMLSchema#string

Lorenza Scotti

http://www.w3.org/2001/XMLSchema#string

P2860

Oral Antidiabetic Agents

AMP-Activated Protein Kinase in Metabolic Control and Insulin Signaling

Bias in meta-analysis detected by a simple, graphical test

Measuring inconsistency in meta-analyses

Meta-analysis in clinical trials

TSC2 mediates cellular energy response to control cell growth and survival

Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin

Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16

Diet and exercise signals regulate SIRT3 and activate AMPK and PGC-1alpha in skeletal muscle

Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.

P304

813-822

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2011-0462

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Mancia

Carlo La Vecchia

Alberico L. Catapano

Antonella Zambon

P577

2012-05-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225072936

http://www.w3.org/2001/XMLSchema#string

P698

22643536

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

3380880

http://www.w3.org/2001/XMLSchema#string